KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial. PMID 41926962 · Lancet Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
[177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study. PMID 41926960 · Lancet Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Treatment of giant cell arteritis: focus on upadacitinib. PMID 41923480 · Expert Opin Pharmacother · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO-TTRansform Trial. PMID 41913562 · Eur J Neurol · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial. PMID 41912809 · Nat Med · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Intensive lipid-lowering strategies and major cardiovascular events in patients aged ≥65 years: A meta-analysis of randomized trial subgroups. PMID 41887159 · Atherosclerosis · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials. PMID 41869512 · JTO Clin Res Rep · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma. PMID 41864163 · ESMO Open · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Mortality Predictions Including Pre-Admission Functional Status in ICU Patients With Delirium-A Substudy of the AID-ICU Trial. PMID 41863137 · Acta Anaesthesiol Scand · 2026-Apr The record is a substudy of the AID-ICU trial (delirium in ICU), which is not an oncology trial, does not involve a drug-containing cancer intervention, and does not present time-to-event efficacy results for an anti-cancer agent. It is a predictive modeling study, not a randomized trial comparing interventions for a malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer. PMID 41861752 · ESMO Open · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2. PMID 41838287 · Dermatol Ther (Heidelb) · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The significance of the WHO/ISH absolute cardiovascular risk prediction scores among recent stroke survivors in Ghana-Insights from the PINGS2 multicenter study. PMID 41836365 · Equity Neurosci · 2026-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial. PMID 41831471 · Lancet Haematol · 2026-Apr 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L S B
旧组与严格 v3 交集 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Immune Checkpoint Inhibitor-Based Adjuvant Treatment Versus Surveillance in Curatively Treated Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis. PMID 41827017 · J Gastroenterol Hepatol · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Randomized, Controlled Study to Evaluate the Safety and Efficacy of Oxygen-Enriched Epithelium-On Corneal Cross-Linking for the Treatment of Keratoconus. PMID 41824263 · Ophthalmol Ther · 2026-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Management of subjects with type 2 diabetes hospitalized in internal medicine units: a cluster-randomized, multicenter study before and after an educational program. PMID 41824238 · Intern Emerg Med · 2026-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Lefamulin versus omadacycline for community acquired bacterial pneumonia: a systematic review and anchored indirect treatment comparison using moxifloxacin as the common comparator. PMID 41823576 · J Comp Eff Res · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma. PMID 41813900 · Nature · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer. PMID 41812623 · ESMO Open · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized double-blind clinical trial evaluating the effectiveness and safety of secondary prophylaxis with oral vancomycin versus placebo in the prevention of recurrence of clostridioides difficile infection in patients receiving systemic antibiotic therapy (PREVAN trial). PMID 41809590 · JAC Antimicrob Resist · 2026-Apr The trial is a randomized, double-blind, placebo-controlled Phase III study with a drug intervention (oral vancomycin) and a time-to-event efficacy endpoint (CDI recurrence-free survival). However, it does not address a human malignant neoplasm; it evaluates a non-oncology infectious disease condition.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia? PMID 41803403 · Leukemia · 2026-Apr The study is an original, randomized, oncology trial with a drug intervention and time-to-event endpoint (OS), but it fails the definitive phase criterion. The metadata does not confirm Phase III/IIIb or Phase II/III status, and the provided text does not state the trial phase. Furthermore, the primary focus is a biomarker/prognostic analysis (post-hoc landmark analysis of monocytes and granulocytes) rather than a primary efficacy report of the randomized comparison. The title and abstract frame it as a prognostic study, not a trial efficacy report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Effect of Losartan in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study. PMID 41800821 · Pharmacotherapy · 2026-Apr The trial is not eligible because the phase is not established as Phase III/IIIb or Phase II/III, and the primary endpoint is a neurotoxicity endpoint, not a malignancy efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
BEAT-BK: An Adaptive, Randomized Controlled Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Kidney-pancreas Transplantation Recipients (BEAT-BK) Study Protocol. PMID 41799026 · Transplant Direct · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A pre-operative two-week very low-calorie diet to reduce steatosis before liver resection (RESOLVE): A multi-centre randomised controlled feasibility trial. PMID 41797062 · Eur J Surg Oncol · 2026-Apr The study is a feasibility trial evaluating a very low-calorie diet (non-drug intervention) before liver resection for liver neoplasms. It is not a Phase III or definitive randomized trial, and no time-to-event efficacy endpoints (e.g., OS, PFS) or Kaplan-Meier analyses are reported. The intervention is not drug-containing.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Risk factors for recurrence of vulvar high-grade squamous intra-epithelial lesions: long-term follow-up of the PITVIN Study (primary imiquimod vs surgery for vulvar intra-epithelial neoplasia). PMID 41791272 · Int J Gynecol Cancer · 2026-Apr The record describes a long-term follow-up of a Phase 3 randomized trial of imiquimod vs surgery for vulvar HSIL. While it meets criteria for oncology, human, randomized, Phase 3, and drug intervention, the efficacy endpoint is recurrence of a pre-cancerous lesion (HSIL), not a time-to-event endpoint for a malignant neoplasm (e.g., OS, PFS, DFS). Therefore, it does not meet the required primary/key secondary time-to-event efficacy endpoint for a human malignant neoplasm. The report is also a secondary analysis (long-term follow-up) rather than a primary efficacy report.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine. PMID 41781546 · Nat Med · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Likelihood ratio test for the disease progression model to measure saved time in Alzheimer's disease. PMID 41773781 · Stat Methods Med Res · 2026-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Suzetrigine for Acute Pain in the Emergency Department: A First-in-Class NaV1.8 Blocker. PMID 41767204 · J Am Coll Emerg Physicians Open · 2026-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial). PMID 41763966 · Ann Rheum Dis · 2026-Apr The study is a randomized Phase III trial of a drug (ozoralizumab, a TNF inhibitor) in rheumatoid arthritis, not a human malignant neoplasm. While it meets criteria for randomized, phase 3, human, drug intervention, and original result, it is excluded because it is non-oncology and the primary endpoint is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, etc.).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Medical thoracoscopy with talc poudrage and indwelling pleural catheter insertion versus medical thoracoscopy with talc poudrage alone for patients with symptomatic malignant pleural effusion (TACTIC): a randomised, controlled phase 3 trial. PMID 41763237 · Lancet Respir Med · 2026-Apr Study is a Phase III randomized trial in oncology with human participants and an original primary result, but it does not meet the core eligibility criteria because it lacks a primary/key time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR) and its intervention is a medical device (IPC) combined with a procedure, not a drug-containing intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of etifoxine versus alprazolam in generalized anxiety disorders with somatic symptoms: A randomized, double-blind, comparative study. PMID 41763071 · J Anxiety Disord · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Renal Flares and Health-Related Quality of Life Among Patients with Lupus Nephritis: A Post Hoc Analysis of Control Arm Data from the LUNAR Phase 3 Clinical Trial. PMID 41761038 · Rheumatol Ther · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical efficacy of Xiaotan Sanjie decoction in treating gastric cancer with peritoneal metastases: A study protocol for a randomized controlled trial. PMID 41756199 · Contemp Clin Trials Commun · 2026-Apr 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy for LDL-C-lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. PMID 41735092 · J Clin Lipidol · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer. PMID 41731117 · Br J Cancer · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study. PMID 41730814 · Lancet Diabetes Endocrinol · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): a FIELD trial substudy. PMID 41730506 · Diabetes Res Clin Pract · 2026-Apr The record describes a pharmacogenetic substudy of the FIELD trial. While the FIELD trial itself is a Phase III randomized trial of a drug (fenofibrate) with time-to-event efficacy endpoints, the specific study is not an oncology trial. Its primary outcomes are diabetic vascular complications and mortality; cancer-related mortality is only one of several secondary mortality endpoints analyzed in the context of a genetic variant. Therefore, it does not meet the core requirement of being a report on an oncology (human malignant neoplasm) clinical trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The differential effects of social support on quality of life in head and neck cancer patients in the United States and China. PMID 41723882 · Eur J Oncol Nurs · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT. PMID 41717679 · Hypertension · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma. PMID 41714403 · Leukemia · 2026-Apr The record describes a translational/biomarker study (miR-29 in follicular lymphoma) that uses a published RCT (SWOG S0016) as a validation cohort for survival correlations. It is not a report of the original, formal, drug-containing, Phase III/IIIb or Phase II/III randomized trial's efficacy results. The drug intervention criterion is not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of polymer oxygenated alginate dressings for healing skin graft donor areas: A phase III randomized controlled trial. PMID 41713054 · Burns · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Classic Hodgkin Lymphoma in the Older Adult: What's New? PMID 41708412 · Hematol Oncol Clin North Am · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Clinical protocol for the K-3 trial: a single-center, patient-blinded, randomized clinical trial addressing anesthesiologic, oncological and patient recovery outcomes of standard flank approach vs supine approach for robot-assisted partial nephrectomy. PMID 41707608 · Surg Oncol · 2026-Apr 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Machine Learning to Predict Outcomes and Dosing Frequency With Aflibercept for Macular Edema Following Central Retinal Vein Occlusion. PMID 41705990 · Ophthalmic Surg Lasers Imaging Retina · 2026-Apr 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma. PMID 41704058 · Br J Haematol · 2026-Apr The record describes a randomized, multicentre trial with a primary EFS endpoint and formal results, but the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. Phase classification cannot be established from the abstract alone.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low-dose fractionated radiotherapy combined with induction chemotherapy in high-risk nasopharyngeal carcinoma: An open-label, randomized phase 2 trial. PMID 41702154 · Oral Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials. PMID 41692019 · Lancet Respir Med · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and Efficacy of Tamoxifen in Patients with Duchenne muscular dystrophy: open Label Extension of TAMDMD Trial. PMID 41691937 · Neuromuscul Disord · 2026-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial. PMID 41690405 · Radiother Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis. PMID 41689889 · Lung Cancer · 2026-Apr The report is a subset analysis (Asian participants) of the MARIPOSA trial. While the analysis itself has formal results, it is not the primary report of the Phase III/definitive trial; it is a secondary/subgroup analysis. The original MARIPOSA trial is likely Phase III (based on drug names and standard trial design for approval), but the report's own metadata does not explicitly confirm the phase of the MARIPOSA trial itself. Therefore, phase3_or_definitive cannot be confirmed from this record alone.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -